TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry
Launched by UNIVERSITÄTSMEDIZIN MANNHEIM · Sep 22, 2011
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Quality Control Registry of a standard treatment with intraoperative radiotherapy during breast conserving surgery with 20 Gy at the applicator surface as an advanced boost followed by a shortened external beam radiotherapy. This is a prospective phase IV study to evaluate real life data of IORT Boost. Study runs in Germany with 13 active centers recruiting. Due to the nature of the study (registry) there is no need for randomization. Inclusion of n = \>1000 patients is planned.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Tumor diameter \< 3,5 cm
- • Informed consent
- Exclusion Criteria:
- • No informed consent
- • Tumor size \> 3,5 cm
- • No indication for a boost
About Universitätsmedizin Mannheim
Universitätsmedizin Mannheim is a leading academic medical center affiliated with Heidelberg University, dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on translational medicine, the institution integrates cutting-edge scientific discovery with patient care, fostering collaboration among multidisciplinary teams. Its state-of-the-art facilities and commitment to ethical research practices position Universitätsmedizin Mannheim as a pivotal contributor to the development of new therapies and medical technologies, ultimately enhancing patient outcomes and contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mannheim, , Germany
Patients applied
Trial Officials
Elena Sperk, MD
Principal Investigator
Universitätsmedizin Mannheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials